Research programme: diabetes/obesity therapy - Bayer/CuraGen

Drug Profile

Research programme: diabetes/obesity therapy - Bayer/CuraGen

Alternative Names: BAY 76-7171; CT052

Latest Information Update: 17 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer; CuraGen Corporation
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 17 Apr 2009 No development reported - Preclinical for Diabetes mellitus in USA (PO)
  • 23 Dec 2005 The collaboration agreement between Bayer and CuraGen has been revised
  • 28 Oct 2004 Bayer and CuraGen announced that an orally active, small molecule compound has been advanced into preclinical development for type 2 diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top